UK listings framework continues to dampen IPO appeal

Lack of capital pool

The London Stock Exchange is at a disadvantage to its competitors as it tries to market itself and the UK as an attractive bourse for companies to list with, but will remain a player despite experts arguing the “scales are tipped against it".

Speaking at a Treasury Select Committee session yesterday (26 April), Jonathan Symonds, chair of GSK, discussed what makes the UK less palatable to list in compared to other markets, especially the US. He pointed the finger at the UK, providing the example of life science companies, which are funded "almost entirely by foreign money". Symonds believed UK companies are looking overseas for their capital raising efforts because the UK "has not participated in the life cycle of UK-generated innovation". FCA's Rathi defends UK listings regime Julia Hoggett, CEO of the London Stock E...